Search
for
Sort by
Research 31–60 of 227
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- Treatment of alopecia areata with JAK inhibitors: a review of the literature
- Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
- Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
- Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Role of topical tofacitinib in autoimmune skin disorders: An expert opinion
- Editorial: Exploring innovative therapies for rare inflammatory skin diseases
- JAK inhibitors in dermatology: The promise of a new drug class
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
- Under Development JAK Inhibitors for Dermatologic Diseases
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Janus kinase inhibitors for alopecia areata: A narrative review
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Impacto del desequilibrio del microbioma del cuero cabelludo en la severidad de la alopecia areata, marcadores inflamatorios y cambios post-tratamiento
- Turning JAK STATic, a peek into the future of dermatology therapeutics
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond